<SEC-DOCUMENT>0001181431-12-035191.txt : 20120607
<SEC-HEADER>0001181431-12-035191.hdr.sgml : 20120607
<ACCEPTANCE-DATETIME>20120607134305
ACCESSION NUMBER:		0001181431-12-035191
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20120607
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120607
DATE AS OF CHANGE:		20120607

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CRYO CELL INTERNATIONAL INC
		CENTRAL INDEX KEY:			0000862692
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-SERVICES, NEC [8900]
		IRS NUMBER:				223023093
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1130

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23386
		FILM NUMBER:		12894347

	BUSINESS ADDRESS:	
		STREET 1:		700 BROOKER CREEK BLVD
		STREET 2:		SUITE 1800
		CITY:			OLDSMAR
		STATE:			FL
		ZIP:			34677
		BUSINESS PHONE:		813-749-2104

	MAIL ADDRESS:	
		STREET 1:		700 BROOKER CREEK BLVD
		STREET 2:		SUITE 1800
		CITY:			OLDSMAR
		STATE:			FL
		ZIP:			34677
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>rrd348164.htm
<TEXT>

<HTML>
<HEAD>
   <TITLE>DC12359.pdf -- Converted by SEC Publisher 4.2, created by BCL Technologies Inc., for SEC Filing</TITLE>
</HEAD>

<BODY bgcolor="#ffffff">


<!--$$/page=-->
<A name="page_1"></A>

<P align="center">
<B><FONT face="serif">UNITED STATES</FONT></B></P>
<P align="center">
<B><FONT face="serif">SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549</FONT></B></P>
<P align="center">
<TABLE><TR><TD align="center" nowrap>
<B><FONT size=4 face="serif">FORM 8-K</FONT></B><BR>
<BR>
<B><FONT face="serif">CURRENT REPORT</FONT></B><BR>
</TD></TR></TABLE>
</P>
<P align="center">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face="serif">PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934</FONT></P>
<P align="center">
<FONT face="serif">Date of Report (Date of earliest event reported): </FONT><U><FONT face="serif">June 6, 2012</FONT></U></P>
<TABLE border=0 cellspacing=1 cellpadding=0>
<TR valign="bottom">
	<TD width=31% nowrap align=left>
&nbsp;
	</TD>
	<TD width=2%>
&nbsp;	</TD>
	<TD width=42% nowrap align=center>
<U><FONT face="serif">CRYO CELL International, Inc.</FONT></U>&nbsp;
	</TD>
	<TD width=2%>
&nbsp;	</TD>
	<TD width=21% nowrap align=left>
&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD width=75% nowrap colspan=3 align=center>
<FONT size=2 face="serif">(Exact Name of Registrant as Specified in its Charter)</FONT>&nbsp;
	</TD>
	<TD width=2%>
&nbsp;	</TD>
	<TD width=21% nowrap align=left>
&nbsp;
	</TD>
</TR>
<TR>
	<TD colspan=5>
&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD width=31% nowrap align=center>
<U><FONT face="serif">Delaware</FONT></U>&nbsp;
	</TD>
	<TD width=2%>
&nbsp;	</TD>
	<TD width=42% nowrap align=center>
<U><FONT face="serif">000-23386</FONT></U>&nbsp;
	</TD>
	<TD width=2%>
&nbsp;	</TD>
	<TD width=21% nowrap align=center>
<U><FONT face="serif">22-3023093</FONT></U>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD width=31% nowrap align=left>
 &nbsp;<FONT face="serif">(State or Other Jurisdiction</FONT>&nbsp;
	</TD>
	<TD width=2%>
&nbsp;	</TD>
	<TD width=42% nowrap align=center>
<FONT face="serif">(Commission File No.)</FONT>&nbsp;
	</TD>
	<TD width=2%>
&nbsp;	</TD>
	<TD width=21% nowrap align=center>
<FONT face="serif">(I.R.S. Employer</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD width=31% nowrap align=center>
<FONT face="serif">of Incorporation)</FONT>&nbsp;
	</TD>
	<TD width=2%>
&nbsp;	</TD>
	<TD width=42% nowrap align=left>
&nbsp;
	</TD>
	<TD width=2%>
&nbsp;	</TD>
	<TD width=21% nowrap align=center>
<FONT face="serif">Identification No.)</FONT>&nbsp;
	</TD>
</TR>
<TR>
	<TD colspan=5>
&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD width=75% nowrap colspan=3 align=left>
 &nbsp;<U><FONT face="serif">700 Brooker Creek Boulevard, Oldsmar, Florida</FONT></U>&nbsp;
	</TD>
	<TD width=2%>
&nbsp;	</TD>
	<TD width=21% nowrap align=center>
<U><FONT face="serif">34677</FONT></U>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD width=75% nowrap colspan=3 align=left>
 &nbsp;<FONT face="serif">(Address of Principal Executive Offices)</FONT>&nbsp;
	</TD>
	<TD width=2%>
&nbsp;	</TD>
	<TD width=21% nowrap align=center>
<FONT face="serif">(Zip Code)</FONT>&nbsp;
	</TD>
</TR>
<TR>
	<TD colspan=5>
&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD width=75% nowrap colspan=3 align=left>
<FONT face="serif">Registrant&#146;s telephone number, including area code: (813) 749-2100</FONT>&nbsp;
	</TD>
	<TD width=2%>
&nbsp;	</TD>
	<TD width=21% nowrap align=left>
&nbsp;
	</TD>
</TR>
</TABLE><BR>
<P align="center">
<TABLE><TR><TD align="center" nowrap>
<U><FONT face="serif">Not Applicable</FONT></U><BR>
</TD></TR></TABLE>
</P>
<P align="center">
<TABLE><TR><TD align="center" nowrap>
<FONT size=2 face="serif">(Former name or former address, if changed since last report)</FONT><BR>
</TD></TR></TABLE>
</P>
<P align="left">
<FONT face="serif">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</FONT></P>
<TABLE border=0 cellspacing=1 cellpadding=0>
<TR valign="bottom">
	<TD width=4% nowrap align=left>
<FONT face="serif">[ ]</FONT>&nbsp;
	</TD>
	<TD width=2%>
&nbsp;	</TD>
	<TD width=93% nowrap align=left>
<FONT face="serif">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD width=4% nowrap align=left>
<FONT face="serif">[ ]</FONT>&nbsp;
	</TD>
	<TD width=2%>
&nbsp;	</TD>
	<TD width=93% nowrap align=left>
<FONT face="serif">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD width=4% nowrap align=left>
<FONT face="serif">[ ]</FONT>&nbsp;
	</TD>
	<TD width=2%>
&nbsp;	</TD>
	<TD width=93% nowrap align=left>
<FONT face="serif">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD width=4% nowrap align=left>
&nbsp;
	</TD>
	<TD width=2%>
&nbsp;	</TD>
	<TD width=93% nowrap align=left>
<FONT face="serif">(17 CFR 240.14d-2(b))</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD width=4% nowrap align=left>
<FONT face="serif">[ ]</FONT>&nbsp;
	</TD>
	<TD width=2%>
&nbsp;	</TD>
	<TD width=93% nowrap align=left>
<FONT face="serif">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD width=4% nowrap align=left>
&nbsp;
	</TD>
	<TD width=2%>
&nbsp;	</TD>
	<TD width=93% nowrap align=left>
<FONT face="serif">(17 CFR 240.13e-4(c))</FONT>&nbsp;
	</TD>
</TR>
</TABLE><BR>

<HR noshade align="center" width="100%" size=2>



<!--$$/page=-->
<A name="page_2"></A>

<P align="left">
<TABLE><TR><TD nowrap>
<B><FONT face="serif">Item 5.02</FONT></B><BR>
</TD></TR></TABLE>
</P>
<P align="left">
<TABLE><TR><TD nowrap>
<B><U><FONT face="serif">Other Events.</FONT></U></B><BR>
</TD></TR></TABLE>
</P>
<P align="left">
<TABLE><TR><TD nowrap>
<B><I><FONT face="serif">Hiring of Chief Scientific Officer.</FONT></I></B><BR>
</TD></TR></TABLE>
</P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face="serif">On June 7, 2012 Cryo-Cell International, Inc. (the &#147;Company&#148;) announced that it has hired, effective June 18, 2012, Linda Kelley, Ph.D. to serve as the Company&#146;s Chief Scientific
Officer. Dr. Kelley is an internationally recognized expert in the cellular therapy field.  She joined the Company from the Dana-Farber Cancer Institute at Harvard where she was the director of the Connell O&#146;Reilly Cell Manipulation Core
Facility. Prior to that, she spent 17 years at the University of Utah where she was director of the Cell Therapy Facility. She established that state&#146;s first umbilical cord blood collection program and was awarded a Center of Excellence in Cell
Therapy and Regenerative Medicine for the State of Utah, which served as a cornerstone for a larger state initiative in Regenerative Medicine - the Utah Science &amp; Technology Research Initiative. She completed her graduate and post-doctoral
training in Immunology and Hematology at Vanderbilt University in Nashville, Tenn., where she served as assistant professor in the Dept. of Medicine.  Dr. Kelley has served on multiple boards and committees that advise on scientific policy and
establish standards and regulations for the cellular therapy field in the U.S. and abroad, often in leadership roles. She served on the Board of Directors of the Foundation for Accreditation of Cellular Therapy (FACT) and as Chair of its Standards
Committee; Chair of the Cord Blood Standards Committee for the National Marrow Donor Program (NMDP); Chair of the Legal and Regulatory Affairs Committee of the International Society for Cell Therapy; reviewer for the AABB Annual Meeting Abstract
Review Committee, and member of the Scientific Advisory Board of Duke Carolinas Cord Blood Bank. Dr. Kelley was one of 12 scientists selected by the Institute of Medicine of the National Academies of Science to advise Congress on how to allocate
&#36;80 million in funding to optimally structure a national cord blood stem cell program.</FONT></P>
<P align="left">
<TABLE><TR><TD nowrap>
<B><I><FONT face="serif">Stock Repurchase Plan.</FONT></I></B><BR>
</TD></TR></TABLE>
</P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face="serif">On June 6, 2012, the Board of Directors of the Company increased the number of shares of the Company&#146;s outstanding common stock that management is authorized to repurchase to up to three million
(3,000,000) shares. The repurchases must be effectuated through open market purchases, privately negotiated block trades, unsolicited negotiated transactions, and/or pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of
the Securities and Exchange Commission or in such other manner as will comply with the provisions of the Securities Exchange Act of 1934.</FONT></P>

<HR noshade align="center" width="100%" size=2>



<!--$$/page=-->
<A name="page_3"></A>

<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face="serif">On December 1, 2011, the Company had previously announced a repurchase plan of up to one million (1,000,000) shares of the Company&#146;s outstanding common stock. At June 6, 2012, the Company had
repurchased 679,582 shares under the repurchase plan.</FONT></P>
<TABLE border=0 cellspacing=1 cellpadding=0>
<TR valign="bottom">
	<TD width=19% nowrap colspan=3 align=left>
<B><FONT face="serif">Item 9.01.</FONT></B>&nbsp;
	</TD>
	<TD width=2%>
&nbsp;	</TD>
	<TD width=54% nowrap align=left>
<B><FONT face="serif">Financial Statements and Exhibits.</FONT></B>&nbsp;
	</TD>
	<TD width=2%>
&nbsp;	</TD>
	<TD width=22% nowrap align=left>
&nbsp;
	</TD>
</TR>
<TR>
	<TD colspan=7>
&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD width=7% nowrap align=left>
<FONT face="serif">(a)</FONT>&nbsp;
	</TD>
	<TD width=2%>
&nbsp;	</TD>
	<TD width=66% nowrap colspan=3 align=left>
<FONT face="serif">Financial Statements of Businesses</FONT>&nbsp;
	</TD>
	<TD width=2%>
&nbsp;	</TD>
	<TD width=22% nowrap align=left>
<FONT face="serif">Not Applicable.</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD width=7% nowrap align=left>
&nbsp;
	</TD>
	<TD width=2%>
&nbsp;	</TD>
	<TD width=66% nowrap colspan=3 align=left>
<FONT face="serif">Acquired.</FONT>&nbsp;
	</TD>
	<TD width=2%>
&nbsp;	</TD>
	<TD width=22% nowrap align=left>
&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD width=7% nowrap align=left>
<FONT face="serif">(b)</FONT>&nbsp;
	</TD>
	<TD width=2%>
&nbsp;	</TD>
	<TD width=66% nowrap colspan=3 align=left>
<FONT face="serif">Pro Forma Financial Information</FONT>&nbsp;
	</TD>
	<TD width=2%>
&nbsp;	</TD>
	<TD width=22% nowrap align=left>
<FONT face="serif">Not Applicable.</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD width=7% nowrap align=left>
<FONT face="serif">(c)</FONT>&nbsp;
	</TD>
	<TD width=2%>
&nbsp;	</TD>
	<TD width=66% nowrap colspan=3 align=left>
<FONT face="serif">Shell Company Transactions</FONT>&nbsp;
	</TD>
	<TD width=2%>
&nbsp;	</TD>
	<TD width=22% nowrap align=left>
<FONT face="serif">Not Applicable.</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD width=7% nowrap align=left>
<FONT face="serif">(d)</FONT>&nbsp;
	</TD>
	<TD width=2%>
&nbsp;	</TD>
	<TD width=66% nowrap colspan=3 align=left>
<FONT face="serif">Exhibits.</FONT>&nbsp;
	</TD>
	<TD width=2%>
&nbsp;	</TD>
	<TD width=22% nowrap align=left>
<FONT face="serif">Not Applicable.</FONT>&nbsp;
	</TD>
</TR>
</TABLE><BR>

<HR noshade align="center" width="100%" size=2>



<!--$$/page=-->
<A name="page_4"></A>

<P align="center">
<TABLE><TR><TD align="center" nowrap>
<B><FONT face="serif">SIGNATURES</FONT></B><BR>
</TD></TR></TABLE>
</P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face="serif">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.</FONT></P>
<P align="center">
<TABLE><TR><TD align="center" nowrap>
<FONT face="serif">Cryo-Cell International, Inc.</FONT><BR>
</TD></TR></TABLE>
</P>
<TABLE border=0 cellspacing=1 cellpadding=0>
<TR valign="bottom">
	<TD width=41% nowrap align=left>
<FONT face="serif">DATE: June 7, 2012</FONT>&nbsp;
	</TD>
	<TD width=2%>
&nbsp;	</TD>
	<TD width=20% nowrap align=left>
<FONT face="serif">By:</FONT>&nbsp;
	</TD>
	<TD width=2%>
&nbsp;	</TD>
	<TD width=33% nowrap align=left>
<FONT face="serif">/s/ Jill M. Taymans</FONT>&nbsp;
	</TD>
</TR>
<TR>
	<TD>
	</TD>
	<TD>
	</TD>
	<TD>
	</TD>
	<TD>
	</TD>
	<TD>
<HR noshade size=1>
	</TD>
</TR>
<TR valign="bottom">
	<TD width=41% nowrap align=left>
&nbsp;
	</TD>
	<TD width=2%>
&nbsp;	</TD>
	<TD width=20% nowrap align=left>
&nbsp;
	</TD>
	<TD width=2%>
&nbsp;	</TD>
	<TD width=33% nowrap align=left>
<FONT face="serif">Jill M. Taymans</FONT>&nbsp;
	</TD>
</TR>
<TR valign="bottom">
	<TD width=41% nowrap align=left>
&nbsp;
	</TD>
	<TD width=2%>
&nbsp;	</TD>
	<TD width=20% nowrap align=left>
&nbsp;
	</TD>
	<TD width=2%>
&nbsp;	</TD>
	<TD width=33% nowrap align=left>
<FONT face="serif">Vice President, Finance</FONT>&nbsp;
	</TD>
</TR>
</TABLE><BR>

<HR noshade align="center" width="100%" size=2>


</BODY>

</HTML>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
